Broadly neutralizing antibodies consistently trap HIV-1 in fresh cervicovaginal mucus from select individuals
Source abstract
Abstract
In addition to direct neutralization and other classical effector functions, IgG possesses a little recognized and thus under-utilized effector function at mucosal surfaces: Fc-mucin bonds enable IgG to trap viruses in mucus. Due to the paucity of envelope glycoproteins that limits the number of IgG that can bind HIV, it remains poorly understood whether IgG-mucin interactions can effectively immobilize HIV in human cervicovaginal mucus (CVM). Here, we obtained 54 fresh, undiluted CVM specimens from 17 different women, and employed high-resolution multiple particle tracking to quantify the mobility of fluorescent HIV virus-like-particles in CVM treated with various HIV-specific IgG. We observed consistent and effective trapping of HIV by broadly neutralizing antibodies (VRC01, PGT121, and 2F5) in a subset of women. While trapping efficacy was not affected by the menstrual cycle, it was positively correlated with appreciable L. Crispatus populations in the microbiome, and negatively correlated with appreciable L. Iners or G. Vaginalis populations. Our work demonstrates for the first time that IgG-mucin crosslinking is capable of reinforcing the mucosal barrier against HIV, and motivates further investigation of passive immunization against vaginal transmission of STIs. STATEMENT OF SIGNIFICANCE: HIV transmission in women primarily occurs vaginally, yet the 3-way interactions between mucins and HIV virions mediated by HIV-binding antibodies in cervicovaginal mucus (CVM) is not well understood. While IgG-Fc possess weak affinity to mucins that trap virus/IgG complexes in mucus, the effectiveness against HIV remains unclear, due to the low number of virion-bound IgG. Here, we discovered that IgG can trap HIV consistently in CVM from select individuals regardless of their birth control status or menstrual cycle phase. IgG-mediated trapping of HIV was moderately associated with microbiome composition. These results suggest that IgG-mucin interactions could potentially reduce HIV transmission and highlight the importance of mucosal secretions in antibody-mediated prevention of HIV and other sexually transmitted infections.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Reproductive tract infections research · Blood groups and transfusion · HIV Research and Treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (62)
Show source-provided references
1. Global HIV & AIDS statistics — 2019 fact sheet | UNAIDS, (n.d.). https://www.unaids.org/en/resources/fact-sheet (accessed February 6, 2020).
2. Unaids, UNAIDS report on the global AIDS epidemic 2013 global report, 2013.
3. The changing epidemiology of HIV in 2013
4. HIV-1 vaginal transmission: cell-free or cell-associated virus?10.1111/aji.12240 ↗
5. Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes10.2147/DDDT.S133170 ↗
6. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women10.1097/QAD.0b013e32834541d9 ↗
7. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana10.1371/journal.pone.0001312 ↗
8. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial10.1016/S0140-6736(10)61086-0 ↗
9. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial10.1016/S0140-6736(08)61842-5 ↗
10. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women10.1056/NEJMoa1602046 ↗
11. Gravity-induced coating flows of vaginal gel formulations: in vitro experimental analysis10.1002/jps.20194 ↗
12. Mucins of the human endocervix10.2741/Gipson ↗
13. Innate and adaptive immune responses in male and female reproductive tracts in homeostasis and following HIV infection10.1038/cmi.2014.41 ↗
14. Barrier properties of mucus10.1016/j.addr.2008.09.008 ↗
15. Innate host defense of human vaginal and cervical mucosae
16. IgG in cervicovaginal mucus traps HSV and prevents vaginal Herpes infections10.1038/mi.2013.120 ↗
17. IgG and IgA content of vaginal fluid during the menstrual cycle - PubMed
18. Antibody diffusion in human cervical mucus10.1016/S0006-3495(94)80802-1 ↗
19. Diffusion of macromolecules and virus-like particles in human cervical mucus10.1016/S0006-3495(01)75844-4 ↗
20. A blueprint for robust crosslinking of mobile species in biogels with weakly adhesive molecular anchors10.1038/s41467-017-00739-6 ↗
21. ZMapp reinforces the airway mucosal barrier against ebola virus10.1093/infdis/jiy230 ↗
22. Herpes simplex virus-binding IgG traps HSV in human cervicovaginal mucus across the menstrual cycle and diverse vaginal microbial composition10.1038/s41385-018-0054-z ↗
23. Distribution and three-dimensional structure of AIDS virus envelope spikes10.1038/nature04817 ↗
24. Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus10.1128/JVI.01899-08 ↗
25. Minimizing biases associated with tracking analysis of submicron particles in heterogeneous biological fluids10.1016/j.jconrel.2015.10.021 ↗
26. Convolutional neural networks automate detection for tracking of submicron-scale particles in 2D and 3D10.1073/pnas.1804420115 ↗
27. Temporal dynamics of the human vaginal microbiota10.1126/scitranslmed.3003605 ↗
28. Vaginal microbiome of reproductive-age women10.1073/pnas.1002611107 ↗
29. An improved dual-indexing approach for multiplexed 16S rRNA gene sequencing on the Illumina MiSeq platform
30. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 210.1038/s41587-019-0209-9 ↗
31. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC0110.1126/science.1192819 ↗
32. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans10.1371/journal.ppat.1003342 ↗
33. Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2f5: vaccine design implications10.1128/JVI.01604-09 ↗
34. Acid production by vaginal flora in vitro is consistent with the rate and extent of vaginal acidification10.1128/IAI.67.10.5170-5175.1999 ↗
35. J. Ongradi, L. Ceccherini Nelli, M. Pistello, M. Bendinelli, S. Specter, Acid sensitivity of cell-free and cell-associated HIV-1: clinical implications, https://Home.Liebertpub.Com/Aid. 6 (2009) 1433–1436. https://doi.org/10.1089/AID.1990.6.1433.10.1089/aid.1990.6.1433 ↗
36. Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women10.1086/427777 ↗
37. Viral sexually transmitted infections and bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data10.1097/OLQ.0b013e3181788301 ↗
38. Bacterial vaginosis assessed by gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection10.1086/657320 ↗
39. Cervicovaginal microbiome dysbiosis is associated with proteome changes related to alterations of the cervicovaginal mucosal barrier10.1038/mi.2015.86 ↗
40. Enhanced trapping of HIV-1 by human cervicovaginal mucus is associated with Lactobacillus crispatus-dominant microbiota10.1128/mBio.01084-15 ↗
41. The cervicovaginal mucus barrier to HIV-1 is diminished in bacterial vaginosis10.1371/journal.ppat.1008236 ↗
42. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies10.1097/QAD.0b013e3283021a37 ↗
43. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples10.1371/journal.pmed.1001251 ↗
44. Impact of bacterial vaginosis, as assessed by nugent criteria and hormonal status on glycosidases and lectin binding in cervicovaginal lavage samples10.1371/journal.pone.0127091 ↗
45. Association of high-risk sexual behaviour with diversity of the vaginal microbiota and abundance of Lactobacillus10.1371/journal.pone.0187612 ↗
46. The effects of reproductive hormones on the physical properties of cervicovaginal fluid10.1016/j.ajog.2014.03.041 ↗
47. Regulation of mucosal immunity in the female reproductive tract: the role of sex hormones in immune protection against sexually transmitted pathogens10.1111/aji.12252 ↗
48. The effect of ethinyl estradiol and drospirenone-containing oral contraceptives upon mucoprotein content of cervical mucus10.1016/j.ejogrb.2012.05.002 ↗
49. Ovarian follicular dynamics during conventional vs. continuous oral contraceptive use10.1016/j.contraception.2005.09.009 ↗
50. Cervical mucus and contraception: what we know and what we don't10.1016/j.contraception.2017.07.168 ↗
51. Increases in endogenous or exogenous progestins promote virus-target cell interactions within the non-human primate female reproductive tract10.1371/journal.ppat.1005885 ↗
52. Role and potential therapeutic use of antibodies against herpetic infections10.1016/j.cmi.2016.12.023 ↗
53. Patterns of HIV/SIV prevention and control by passive antibody immunization10.3389/fmicb.2016.01739 ↗
54. Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC1610.1038/mi.2016.8 ↗
55. Three-dimensional structure of herpes simplex virus from cryo-electron tomography10.1126/science.1090284 ↗
56. Broadly neutralizing antibody-mediated protection against simian-HIV infection among macaques with vaginal sexually transmitted infections10.1097/QAD.0000000000003472 ↗
57. Sialidases (neuraminidases) in bacterial vaginosis and bacterial vaginosis-associated microflora10.1128/jcm.30.3.663-666.1992 ↗
58. Robust antigen-specific tuning of the nanoscale barrier properties of biogels using matrix-associating IgG and IgM antibodies10.1016/j.actbio.2019.03.023 ↗
59. K. Sharif, O. Olufowobi, The Structure, Chemistry and Physics of Human Cervical Mucus, The Cervix: Second ed.. (2009) 155–168. doi:10.1002/9781444312744.CH11.10.1002/9781444312744.ch11 ↗
60. The effects of hormones and vaginal microflora on the glycome of the female genital tract: cervical-vaginal fluid10.1371/journal.pone.0158687 ↗
61. Hormonal contraceptive use and risk of HIV-1 disease progression10.1097/QAD.0b013e32835ad473 ↗
62. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples10.1093/infdis/jir747 ↗